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The selective delivery of siRNAs in a cell type-specific manner represents the major challenge for the application 
of RNA interference for disease treatment. Aptamers have great potentials as carriers for tumor specific siRNA 
delivery. With the nature of nucleic acid, aptamers can be ease of modification and editing. Novel bivalent 
aptamer-dual siRNA chimera (PSMA aptamer- survivin siRNA -EGFR siRNA -PSMA aptamer, PSEP) was 
developed by fusing two siRNAs (specific to EGFR and survivin) between two PSMA aptamers. Bivalent 
aptamer offers increased siRNA internalization compared with monovalent counterpart. PSEP chimera is able 
to inhibit EGFR and survivin simultaneously in a cell type-specific manner. In PSMA expressing tumor 
xenografts, PSEP significantly inhibits tumor growth and angiogenesis. Our results highlight that co-delivery of 
multiple siRNAs with bivalent aptamer represents a novel approach for targeting combination therapy. 
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Aptamers are synthetic single stranded DNA or RNA that 
can bind to a wide range of targets, including small organic 
molecules, peptides, proteins, nucleic acids, and whole cells 
with high affinity and specificity. Aptamers are generated 
from an iterative process called systematic evolution of 
ligands by exponential enrichment (SELEX), first established 
in 1990s by Ellington and Gold [1, 2]. Ellington reported that a 
selected RNA molecule can specifically bind to organic dyes, 
and Gold demonstrated that an RNA could interact with T4 
DNA polymerase. Since then, aptamers have become a 
notable class of targeting ligand for both diagnostics and 
therapeutics.  
As nucleic acid-based molecules, aptamers possess 
significant advantages over antibodies including ease of 
modification, ease of production, low cost, low 
immunogenicity, low toxicity and small size, all of which 
make aptamers ideal candidates for targeted cancer therapy. 
Cancer is highly heterogeneous and complex, particular at 
advanced stages. Single-agent treatments exhibit limited 
activity in clinical setting because cancer cells are able to 
switch to alternative survival pathways. Combination therapy 
to target several oncogenic pathways simultaneously, 
therefore, may have better efficacy in eradicating tumors. 
Current chemical drug combination is associated with 
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overlapping toxicity to normal organs and quickly developed 
drug resistance. Although kinase inhibitor combinations 
show the efficacy and certain molecule targeting, most kinase 
inhibitors are able to target on multiple kinases (low 
specificity), and combination of different kinases may easily 
cause increased toxicity like other chemical drugs. 
Combination of monoclonal antibodies are usually more 
specific, however, antibodies cannot block intracellular 
targets and have high immunogenicity due to their membrane 
impermeability and recognition by host as foreign.  
siRNA has great potential for sequence-specific silencing 
of any genes and has emerged as a promising new 
therapeutic paradigm for “undruggable” targets [3-5]. 
However, cell type -specific delivery of siRNA in vivo still 
represents a major technical hurdle [6]. Carriers using small 
molecules, lipids, peptides and polymers have been linked 
with siRNA for delivery of siRNA to diseases cells [7]. 
Considering the complex physical and chemical structures of 
various formulations, current siRNA delivery vehicles face 
difficulties in large-scale production and regulatory approval 
of clinical uses. 
Aptamer-siRNA chimera (AsiC), employing only RNA 
molecules, is emerging as a highly promising approach for 
cell type-specific RNA interference (RNAi). Cell-based 
SELEX allows the selection of internalized aptamer, which 
can introduce the intracellular delivery of cargo through 
receptor-mediated endocytosis [8, 9]. Aptamers have specific 
3-dimentional structures for target binding, and specific 
binding capability can be kept in vivo. Aptamer-siRNA 
chimera has shown the advantages of low off-target effect 
and low immunogenicity. On the contrary, small chemical 
drugs suffer severe off-target effect that can target normal 
organs, and antibody -based therapeutic can incur strong 
immunogenicity. As a single-component entity, AsiC also 
has advantages in ease of synthesis and high tissue 
penetrability. Importantly, AsiC-based drugs can utilize 
endogenous enzymes (e.g. dicer, argonaute) and trigger gene 
silencing in cell type- and mRNA sequence-specific manner. 
Therefore, AsiC can provide selective and effective 
inhibition of any protein targets that can locate in cell 
membrane, cytoplasm and nucleus. CD4 aptamer-tat/rev 
siRNA chimera can inhibit HIV transmission [10]. PSMA 
aptamer-PLK1siRNA enables the regression of prostate 
cancer [11]. CTLA4 aptamer-STAT3 siRNA inhibits 
Figure 1. Design and characterization of bivalent aptamer-dual siRNA chimera. (a) Structure of PSEP: PSMA aptamer-survivin 
siRNA-EGFR siRNA-PSMA aptamer. PSEP chimera consists of a bivalent PSMA aptamer and two siRNAs specific to survivin and EGFR, 
respectively. Each antisense strand of siRNAs has a 2-nt overhang at the 3′ end. (g) Detection of internalization. C4-2 cells were treated with 
Cy3-labeled PSEP (bivalent PSEP aptamer), PSEM ( monovalent PSMA aptamer), or MSEM ( bivalent non-targeting MG aptamer ) for 2 h at 37 
°C. Cells were washed with DPBS plus 0.5 M NaCl to remove surface bound RNAs. The amount of fluorescently labeled chimeras that 
internalized into cells was measured using flow cytometry. The fluorescent intensity of PSEP has about 1-fold increase compared with 
monovalent counterpart PSEM. 
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tumor-associated Tregs and reduces tumor burden in multiple 
mouse tumor models [12]. EpCAM aptamer-survivin siRNA 
can reverse doxorubicin resistance and increase survival time 
in mice bearing chemoresistant tumors [13]. 
Most current chimeras are designed as the fusion of one 
aptamer with one siRNA [11, 12, 14-16]. However, it is important 
to simultaneous delivery of multiple siRNAs in one chimera. 
In recent studies, we have designed and developed a bivalent 
PSMA aptamer for co-delivery of two siRNAs (specific to 
EGFR and survivin) as shown in Figure 1a. Bivalent aptamer 
is expected to have antibody-like properties in terms of 
inducing cell activation by cross-linking two receptors. Many 
studies have shown that bivalent ligands can induce receptor 
clustering which will trigger signaling transduction and cell 
activation [17, 18]. For example, bivalent antibody can form 
non-covalently crosslinked complex with the BCR (B cell 
antigen receptor), but not monovalent single chain antibody. 
BCR clustering can change membrane organization and elicit 
robust calcium signals [19]. Ligand induced receptor 
dimerization represents a powerful regulatory mechanism 
that can activate intracellular signal pathways [20]. Bivalent 
ligands enable easily induction of receptor dimerization. In 
our studies, to increase the specificity, binding avidity and 
internalization of aptamer-siRNA chimera, we designed a 
bivalent aptamer to facilitate the engagement of cell surface 
protein and trigger cell activation [21]. Activated cells will 
allow increased cargo internalization [22]. PSMA aptamer 
against prostate-specific membrane antigen (PSMA) has 
been proven to enable efficient delivery of siRNAs into 
PSMA-expressing prostate cancer (PCa) cells [23, 24]. In our 
studies, two important oncogenes including EGFR and 
survivin were targeted and fused with two PSMA aptamers. 
By fusing of two aptamers and two siRNAs, we have 
developed a novel bivalent aptamer-dual siRNA chimera: 
PSMA aptamer-survivin siRNA-EGFR siRNA-PSMA 
aptamer (PSEP) [25]. We proved that PSEP chimera can be cut 
by dicer. Two tandem siRNAs spaced with four “U”s warrant 
the cleavage with dicer enzyme but not inactivating two 
genes, since dicer is able to measure and cut 21-25-nt RNA 
duplex [26-28]. We have designed survivin anti-sense and 
EGFR anti-sense strands with 2-nt overhang at the 3′ end of 
siRNAs, which will aid the siRNA-RISC (RNA-induced 
silencing complex) formation (Figure 1a). It is worth 
emphasizing, in the design, it is important to exam whether 
there are significant complementarities among aptamer and 
siRNAs. No significant complementarity will ensure the 
correct folding by annealing.  
We have demonstrated that bivalent aptamer offers 
increased siRNA internalization compared with monovalent 
aptamer. C4-2 cells were treated with Cy3-labeled chimeras 
followed by washing with 0.5M NaCl containing DPBS to 
remove surface bound chimeras. The amount of internalized 
chimeras was quantitated using flow cytometry. As shown in 
Figure 1b, the fluorescence intensity in PSEP treated C4-2 
cells have increased about 1-fold compared with that in 
monovalent PSEM-treated cells, the results confirm the 
advantage of bivalent aptamer over the monovalent 
counterpart in promoting siRNA internalization. 
Unmodified RNA aptamers are susceptible to 
nuclease-mediated degradation. RNA aptamers can be 
modified by replacing ribose 2’-OH group with fluoro (F), 
amino (NH2), or O-methyl (OCH3). Because ribonucleases 
select 2′-OH group for cleavage of phosphodiester bonds. 
The ribose 2’-OH modified aptamers have significantly 
increased nuclease resistance while also enhancing binding 
affinity. In the process of synthesis of PSEP, 2′ 
F-pyrimidines are incorporated into entire chimera via in
vitro transcription. We have characterized the serum stability
of 2’ F-modified PSEP in denaturing gel electrophoresis. We
incubated PSEP chimera in PBS containing 50% fresh
human serum for 1, 2, 3 and 4 h. Electrophoresis revealed
that 2′ F-modified PSEP did not show detectable degradation
within 4 h, and over 60% of modified RNA does not have
degradation for 24h. On the contrary, degraded RNA pattern
was observed for unmodified PSEP as early as at 1 h
incubation.
Notably, bivalent aptamer and dual siRNA chimera will 
have longer circulation time than aptamer and siRNA alone. 
Most aptamers and siRNAs are 5-20 Kd and are therefore 
susceptible to renal filtration since renal glomerulus has 
30-50 Kd of molecular mass cutoff.  To overcome short 
circulation half-life, PEG has been conjugated with aptamer 
-siRNA chimera to increase circulation time in vivo [11]. In
our new chimera, the size of PSEP is bout 59Kd, which is
much larger than current PSMA aptamer-siRNA chimeras [11, 
29] (around 29Kd). We envision that chimera with a bivalent
aptamer and dual siRNAs should possess increased
circulating half-life and reduced renal excretion. Owing to
being nucleic acids, PSEP will perform better than PEG in
ease of clearance. We demonstrated that PSEP chimera
specifically and effectively suppresses the endogenous
expression of EGFR and survivin in PSMA expressing PCa
cells, and clearly inhibits tumor growth in mouse models.
Notably, co-delivery of two siRNAs (EGFR and survivin)
significantly inhibit tumor angiogenesis. Our work is the first
time report that two different siRNAs can be simultaneously
delivered by a bivalent aptamer. Co-delivery of two siRNAs
in one RNA chimera provides a new and efficient approach
for combination therapy. Since the system is highly modular,
our work can be used to design many co-delivery systems by
using siRNAs and aptamers.
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Conclusions 
Aptamer and siRNAs are highly compatible with 
combinational therapy, and may address the limitations of 
current combination treatments with antibodies and small 
chemical drugs in terms of immunogenicity and systemic 
toxicity. Aptamers opened a new horizon for targeting cancer 
treatment. Concomitant delivery of multiple siRNAs with 
bivalent aptamer will be potential to provide synergistic 
efficacy for cancer therapy. 
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